Emcure Pharmaceuticals Ltd
Ticker: EMCURE
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
1364.50
Market Cap
25866.12
Debt/Equity
0.2203
ROE %
17.553
PB
5.5727
Promoter %
77.912
Pledge %
0.032
1Y Rev Growth %
18.667
5Y Rev Growth %
9.204
NP Margin %
8.550
NP Margin 5Y Avg %
8.848
Trading Reference
1M Return %
-0.675
6M Return %
43.360
1Y Return %
-7.873
% Away 52W High
12.345
% Away 52W Low
53.487
Daily Volume
85791
Investment Verdict
Risky
Score 59/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 48/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Emcure Pharmaceuticals Ltd is likely to experience moderate upside potential in the medium-term, with key resistance levels around 850 and support levels near 700. The stock is currently trading above its 50-day EMA, indicating bullish momentum, but volume trends suggest caution as buying interest may be waning.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Shyam Metalics and Energy Ltd
Shyam Metalics and Energy Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
Z
ZF Commercial Vehicle Control Systems India Ltd
ZF Commercial Vehicle Control Systems India Ltd shows potential for growth in a transitioning sector, but faces challenges in profitability and valuation metrics.
View details
F
Firstsource Solutions Ltd
Firstsource Solutions Ltd shows potential with consistent growth but faces challenges in profitability and competitive pressures.
View details
E
EIH Ltd
EIH Ltd shows potential in a recovering sector but faces challenges in growth consistency and market competition.
View details
A
Anand Rathi Wealth Ltd
Anand Rathi Wealth Ltd shows potential for growth in a competitive sector, but faces challenges in profitability and valuation metrics.
View details
W
Wockhardt Ltd
Wockhardt Ltd presents several risks, particularly in growth consistency and balance sheet strength, making it a risky investment at this time.
View details
A
Aegis Logistics Ltd
Aegis Logistics Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
M
Manappuram Finance Ltd
Manappuram Finance Ltd shows potential for growth but is facing several challenges that could impact its performance.
View details
O
Ola Electric Mobility Ltd
Ola Electric Mobility Ltd shows potential in a growing sector but faces significant challenges in execution and profitability.
View details
N
Navin Fluorine International Ltd
Navin Fluorine International Ltd shows potential for growth in a favorable sector, but investors should be cautious of valuation and execution risks.
View details
T
Tata Chemicals Ltd
Tata Chemicals Ltd shows potential with a decent score, but investors should be cautious due to fluctuating profitability and valuation concerns.
View details
A
Aditya Birla Sun Life AMC Ltd
Aditya Birla Sun Life AMC Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised for new investments.
View details
P
Piramal Enterprises Ltd
Piramal Enterprises has potential but faces challenges in growth consistency and market valuation.
View details
R
Ramco Cements Limited
Ramco Cements shows potential for growth but faces challenges in profitability and valuation metrics.
View details
F
Force Motors Ltd
Force Motors Ltd presents several risks with inconsistent growth and profitability, making it a risky investment at this time.
View details
H
HBL Engineering Ltd
HBL Engineering Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Emcure Pharmaceuticals Ltd is a leading Indian pharmaceutical company committed to enhancing healthcare through innovative solutions. With a diverse portfolio of products, it caters to various therapeutic areas, ensuring quality and accessibility for patients across India and beyond. Emcure's focus on research and development drives its mission to deliver effective treatments and improve patient outcomes. The company is dedicated to sustainability and ethical practices, making it a trusted partner in healthcare.
- Established leader in the Indian pharma sector
- Wide range of therapeutic products
- Strong commitment to R&D and innovation
- Focus on quality and patient accessibility
- Ethical practices and sustainability initiatives
Investment Thesis
Emcure Pharmaceuticals Ltd stands out due to its strong promoter credibility, robust growth in digital services, and attractive valuation relative to peers. This positions the company for sustained growth and value creation in the pharmaceutical sector.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital health services aligns with industry trends.
- Attractive valuation compared to peers presents a compelling entry point.
- Diverse product portfolio mitigates risks and captures market opportunities.
- Focus on innovation and R&D supports long-term growth prospects.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Strong pipeline of new drugs
- Expansion into international markets
- Strategic partnerships with other firms
Risks ⚠️
- Regulatory challenges in drug approvals
- Intense competition in the sector
- Dependence on key products
- Market volatility affecting stock price
Peer Perspective
Emcure Pharmaceuticals trades at a discount to peers like Sun Pharma and Dr. Reddy's, with a focus on margin stability. A rerating could occur if Emcure demonstrates consistent growth in its specialty segment.
Future Outlook
Emcure Pharmaceuticals Ltd is well-positioned for growth, driven by its robust pipeline and market expansion. However, successful execution and effective cost control will be crucial to fully realize its potential in the evolving pharmaceutical landscape.
AI FAQs for Retail Users
- Q: What does Emcure Pharmaceuticals do?A: Emcure Pharmaceuticals is a leading Indian pharmaceutical company focused on developing, manufacturing, and marketing a wide range of medicines.
- Q: Is Emcure Pharmaceuticals listed on the stock exchange?A: Yes, Emcure Pharmaceuticals is publicly listed and trades on the National Stock Exchange of India.
- Q: What are the main products of Emcure Pharmaceuticals?A: Emcure offers a variety of products including formulations, active pharmaceutical ingredients, and biosimilars across multiple therapeutic areas.
- Q: What factors can affect Emcure's stock price?A: Factors include market conditions, company performance, regulatory changes, and overall economic trends in the pharmaceutical sector.
- Q: How can I invest in Emcure Pharmaceuticals?A: You can invest by purchasing shares through a registered stockbroker or trading platform that offers access to Indian stocks.
📊 Stock Investment Checklist (100 Points)
Emcure Pharmaceuticals Ltd • Updated: 2025-09-17 15:40:19
-
10BusinessHighPharmaceutical sector is essential but faces regulatory challenges.
-
10GrowthHighConsistent revenue growth, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighP/E and P/B ratios are higher than industry averages.
-
7BalanceHighModerate debt levels with adequate liquidity.
-
6GovernanceGoodPromoter holding is stable, but some pledging exists.
-
5DriversGoodGrowth drivers are present, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is mixed with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Emcure Pharmaceuticals shows potential for growth, but faces several challenges that could impact its performance.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100